Kurt Browning
Chief Executive Officer
Kurt Browning is the Chief Executive Officer of Medvantx, bringing deep executive experience across healthcare, specialty pharmacy, supply chain, and operations. He has a proven track record of driving execution and growth in both public and private equity-backed organizations. Kurt previously served as Chief Financial Officer of Medvantx, where he led the company’s financial strategy and played a key role in advancing operational transformation. He continues to work closely with leadership to strengthen execution, scalability, and cross-functional alignment across the organization. Prior to Medvantx, Kurt held financial leadership roles at Synchrony Health Services, Onco360, and Quantix. At Onco360, he helped scale the organization into one of the largest specialty pharmacies in the United States while maintaining operational discipline. He also built a strong foundation in logistics and supply chain at UPS Healthcare, supporting complex, highly regulated distribution models.
Ellie Jenkins
Head of Human Resources
Ellie brings nearly 20 years of experience, 10 years directly in Human Resources from both public and private sectors. She has a passion for strategic business partnering and talent management. Most recently, Ellie served as Associate Director, HR at Currax Pharmaceuticals. Prior to that, she held various senior HR leadership roles at News Corp and Fresenius Medical Care. Her extensive experience spans global geographies and business scales, bringing a wealth of expertise to Medvantx. Ellie holds a Bachelor of Science from Vanderbilt University and an MBA from Middle Tennessee State University. In her previous roles, Ellie has successfully led HR teams with multi-site responsibilities and across varied disciplines.
Mark Jara
SVP, Samples Platform
Mark Jara leads the Samples Platform at Medvantx, where he is responsible for integrating and expanding the capabilities of RxS via acquisition, the sample management company he co-founded. With over 25 years in pharmaceutical commercialization and compliance, Mark brings deep expertise across eSampling, field-rep, direct-to-practitioner, and hospital-based programs. His leadership strengthens Medvantx’s ability to deliver end-to-end solutions that connect healthcare providers and patients through a unified patient access ecosystem. He was named to the PharmaVOICE 100 in 2018 for his leadership in advancing access and digital transformation. Mark also served as a board member and partner to the PDMA Sharing Alliance, where he spoke annually on compliance and technology trends shaping the future of sample accountability. He holds a BA in Information Systems from Rutgers/NJIT and an MS in Management from Stevens Institute of Technology. Mark is a committed advocate for Alzheimer’s awareness and research. Inspired by personal family experience, he participates annually in the Walk to End Alzheimer’s and supports efforts that promote early intervention, patient support, and caregiver resources.
Brian Bernstein
VP, Business Development
Brian Bernstein is the Vice President of Business Development at Medvantx, where he leads strategic partnerships with pharmaceutical manufacturers, biotech companies, and healthcare organizations. In this role, Brian is responsible for driving commercial growth, expanding Medvantx’s manufacturer relationships, and identifying new opportunities across pharmacy services, patient assistance programs, and medication access solutions. With more than two decades of experience in the pharmaceutical and healthcare services industries, Brian has a strong background in building client relationships, developing strategic partnerships, and bringing new programs to market. He works closely with manufacturers and partners to align Medvantx’s capabilities with evolving patient access and commercialization needs, helping organizations improve patient access while supporting successful therapy launches and ongoing program growth.
Mikaela Ekobena
Director, Operations
Mikaela is the Director of Operations, leading Order Entry and Production pharmacy technicians across two sites and remotely throughout the country. She joined Medvantx in 2017 as a staff pharmacist and progressed through leadership roles within the company including Pharmacist in Charge and Associate Director of Pharmacy Production, where she gained proficiency in regulatory compliance, quality performance, and operational excellence. Mikaela brings a decade of experience in the pharmacy industry, with background in mail order, retail, and hospital pharmacy. She holds a dual Bachelor’s Degree in Biology and Pharmaceutical Sciences as well as a Doctorate of Pharmacy from South Dakota State University. With a continued commitment to quality and regulatory expertise, Mikaela has obtained a Lean Six Sigma Green Belt and licensure as a pharmacist in 23 states and territories.
Nate Jarvis
Vice President, Medical Affairs
Nate is the Vice President of Medical Affairs, leading Quality, Compliance, and Pharmacy. Previously, Nate served as the Vice President of Pharmacy Operations with responsibility for Order Entry, Pharmacy, Production, and Supply Chain for Medvantx for three years. He joined Medvantx in 2021 as the Pharmacy Operations Manager of the Kentucky pharmacy. Nate has over 15 years of experience in the pharmacy industry, with expertise in specialty, mail order, and retail pharmacy. He holds both a PharmD and an MBA degree from Sullivan University and is a licensed pharmacist in 13 states.
Evan Brugger
Vice President, Strategy & Business Development
Evan serves as the Vice President of Strategy & Business Development at Medvantx, bringing a wealth of experience from his previous role at Accord Capital, a healthcare services-focused investment firm. At Accord, Evan played a pivotal role in supporting portfolio companies across the healthcare sector, conducting due diligence for acquisitions and divestitures, and delivering key industry insights. His collaboration with Medvantx during this time led to his full-time transition to the company in August 2022. Before his tenure at Accord, which began in 2018, Evan honed his expertise as a corporate financial analyst, where he consistently sought opportunities to enhance impact through automation and process improvements within Fortune 500 companies. Evan holds a Bachelor’s degree in Economics and Finance, as well as a Master’s in Finance-Risk Management, both from the University of Tulsa.

